A5027122618- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Pharmaceutical Economics and Policy
- Vascular Tumors and Angiosarcomas
- Patient-Provider Communication in Healthcare
- Peptidase Inhibition and Analysis
- Patient Satisfaction in Healthcare
- Colorectal Cancer Surgical Treatments
- Cardiac tumors and thrombi
Baylor University Medical Center
2011-2025
Texas Oncology
2014-2024
The US Oncology Network
2011-2024
Diagnostics for the Real World (United States)
2023
McKesson (United States)
2012-2021
Carolinas Healthcare System
2017
Levine Cancer Institute
2017
Sunnybrook Health Science Centre
2009-2010
St. Michael's Hospital
2009-2010
Regional Cancer Center
2010
PURPOSE Retroperitoneal soft tissue sarcomas are rare tumors. Studies characterizing long-term follow-up and patterns of recurrence limited. The purpose this analysis is to identify prognostic factors associated with survival after resection retroperitoneal sarcomas. METHODS Between July 1, 1982, June 30, 1990, 198 adult patients were identified from our prospective sarcoma database carrying the diagnosis who eligible for > or = 5 years follow-up. Of these, 48 (25%) documented be alive...
Learning Objectives After completing this course, the reader will be able to: Describe how academic oncologists view costs of new treatments in their treatment recommendations.Discuss oncologists’ perceptions cost and benefit one light published results.Describe cost-effectiveness relative to previously accepted standards. CME Access take test online receive 1 AMA PRA category credit at CME.TheOncologist.com
A national survey of medical oncologists indicates that rising cancer treatment costs are influencing clinical practice, even as tend not to communicate with patients about costs. The shows 84 percent say patients' out-of-pocket spending influences recommendations. Only 43 always or frequently discuss patients. Among those surveyed, 79 favor more comparative effectiveness research; 80 support cost-effectiveness data, although only 42 feel well prepared interpret it. results suggest...
Oncologists in the United States and Canada work different health care systems, but physicians both countries face challenges posed by rising costs of cancer drugs. We compared their attitudes regarding cost-effectiveness medications related policy.Survey responses a random sample 1,355 238 Canadian medical oncologists (all outside Québec) were compared.Response rate was 59%. More US (67% v 52%; P < .001) favor access to effective treatments regardless cost, while more Canadians only if they...
The experience of undergoing surgery is known to induce a short-term, fight-or-flight physiological stress response. As an optimum immune response at the site would enhance tissue repair, we examined surgical stress-induced cell redistribution profiles as predictors, and potential mediators, short long-term postoperative recovery. We tested priori hypothesis that predefined adaptive observed during will predict enhanced recovery.This prospective longitudinal study involved fifty-seven...
Multiple therapeutic options now exist for metastatic non-small-cell lung cancer (mNSCLC). In this study we evaluated treatment patterns and outcomes in mNSCLC patients who received first-line (1L), second-line (2L), third-line (3L) therapy.A retrospective, observational cohort was conducted using an electronic health record database of initial from January 2012 through April 2016, with follow-up June 2016. Patient characteristics were characterized. Overall survival (OS) assessed the...
Abstract Purpose Treatments for advanced non-small cell lung cancer (NSCLC) have evolved to include targeted and immuno-oncology therapies, which demonstrated clinical benefits in trials. However, few real-world studies evaluated these treatments the first-line setting. Methods Adult patients with NSCLC who initiated treatment chemotherapy, therapies (TT), or immuno-oncology–based regimens US Oncology Network (USON) between March 1, 2015, August 2018, were included followed up through...
This study investigated biomarker testing and biomarker-guided treatment among patients with metastatic NSCLC in a real-world setting. retrospective examined adult diagnosed de novo mNSCLC between 01-Jan-2016 30-Sep-2019, follow-up through 31-Dec-2019 using The US Oncology Network structured electronic health records data, chart review for subset. Of 2257 patients, 76.3% had results ≥1 driver mutation (DM) or programmed death ligand-1 (PD-L1) during the observation period. proportion all 4...
Abstract Purpose: Programmed cell death-1 (PD-1) receptor inhibitors have shown efficacy in head and neck squamous carcinoma (HNSCC), but treatment failure or secondary resistance occurs most patients. In preclinical murine models, inhibition of Bruton's tyrosine kinase (BTK) induces myeloid reprogramming that subsequently bolsters CD8+ T responses, resulting enhanced antitumor activity. This phase 2, multicenter, open-label, randomized study evaluated pembrolizumab (anti–PD-1 monoclonal...
Bevacizumab significantly extends progression-free survival (PFS) and overall (OS) times when combined with initial chemotherapy continued as monotherapy until disease progression or unacceptable toxicity in patients nonsquamous non-small cell lung cancer (NSCLC). In clinical practice, bevacizumab is sometimes discontinued after completion of chemotherapy. This retrospective analysis the US Oncology network's electronic medical records evaluated association between PFS OS to (BTP) among...
Amid calls for physicians to become better stewards of the nation's health care resources, it is important gain insight into how think about cost-effectiveness new treatments. Expensive cancer treatments that can extend life raise questions whether are prepared make "value money" trade-offs when treating patients. We asked oncologists in United States and Canada much benefit, additional months expectancy, a drug would need provide justify its cost warrant use an individual patient. The...
Purpose . To assess epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma (mSTS) patients in USA community oncology practices. Methods This retrospective, descriptive study used US Oncology’s iKnowMed electronic health records database. Adults (≥18 years) with mSTS at least two visits between July 2007 June 2010 were included. Key practice overall survival (OS), progression-free (PFS). Results 363 (174 treated 189 untreated) met the prespecified exclusion/inclusion...
The medical record serves as an important source of information regarding the care process, but few studies have examined whether thoroughness documentation is associated with outcomes.The objectives this study were to analyze initial visit note for 513 patients presenting acute musculoskeletal pain, compare by physician specialty, and determine was clinical improvement or patient satisfaction.A structured abstraction performed examine treating physicians documented key historical physical...
Objective. To determine how oncologists value quality-enhancing v. life-prolonging outcomes attributable to chemotherapy. Methods. The authors surveyed a random sample of 1379 US medical (members the American Society Clinical Oncology), presenting them with 2 scenarios involving hypothetical new chemotherapy drug. Given their responses, derived implicit cost-effectiveness ratios each physician attributed and chemotherapies. Results. received responses from 58% surveyed. On average, implied...
Introduction There is a need to understand the current treatment landscape for LA HNSCC in real-world setting. Methods This retrospective study assessed outcomes and patterns of 1,158 adult patients diagnosed with locally advanced (stage III-IVB) initiating chemoradiotherapy (CRT) within period January 2015 December 2017 large network US community oncology practices. Structured data were abstracted from electronic health records. Demographic, clinical characteristics analyzed descriptively...
TPS8655 Background: Mutations in STK11 and KEAP1, present approximately 20% 15% of patients (pts) respectively with NSQ mNSCLC, lead to an immunosuppressive tumor microenvironment are associated inferior clinical outcomes anti-PD-(L)1 based chemo-immunotherapy, especially when co-mutated KRAS. Pts tumors bearing STK11, KEAP1and/or KRAS mutations may benefit from combinations CTLA-4 inhibitors, aimed at increasing immune responses. In the phase 3 POSEIDON trial (NCT03164616), first-line (1L)...
Aim: Cetuximab was approved in 2008 for treating recurrent/metastatic (R/M) head-and-neck squamous-cell carcinoma (HNSCC), and this study assessed the utilization of cetuximab R/M-HNSCC a real-world setting. Materials & methods: Adult patients with R/M-HNSCC, who initiated systemic therapy between 1 September 2011 31 December 2014 followed through 2015, were identified from iKnowMed electronic-health-records database (McKesson Specialty Health) supplemented manual chart-abstraction. Results:...
To investigate the relationship between framing of survival gains and perceived value cancer care.Through a population-based survey 2040 US adults, respondents were randomized to one two sets hypothetical scenarios, each which described benefit for new treatment as either an increase in median time (median survival), or probability given length (landmark survival). Each respondent was presented with randomly selected scenarios different prognosis improvements, asked about their willingness...
Aim: To evaluate the real-world impact of brain metastases (BM) among patients with EGFR mutation-positive (EGFRm) metastatic non-small-cell lung cancer (NSCLC). Materials & methods: This retrospective, observational matched cohort electronic health record study assessed adults EGFRm NSCLC with/without BM. Results: Among 402 split equally between both cohorts (±BM), majority were Caucasian (69%), female (65%) and adenocarcinoma (92%). Overall symptom burden ancillary support service use...